The company has signed the joint venture agreement with SeQuent to develop, manufacture and sell veterinary products including both API (active pharmaceutical ingredients) and formulations to cater to the global market, Shasun Pharmaceuticals said in a filing to the BSE.
Last year, the companies had inked a Letter of Intent (LOI) to form the joint venture firm.
"In line with the joint venture agreement, company has also executed today a slump sale agreement, transferring its Vizag facility to JV Company," Shasun said.
Shasun shares were trading at Rs 76.25 apiece on the BSE in the afternoon trade, down 1.49 per cent from its previous close.